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Abstract
Background and Objective: The prevalence of obesity is increasing both worldwide and locally in India. It is considered a major health
problem and often leads to other associated diseases such as type 2 diabetes, ischemic heart diseases, stroke and cancer. In the present
study, the effects of powder of  Rosa  damascena  flowers on high-fat diet-induced obesity in  Wistar  albino  rats  were  examined.
Materials and Methods: Female Wistar albino rats fed with a High Fat Diet (HFD) (p.o) for 6 weeks were used to induce obesity. Powder
of R. damascena (214 mg kgG1 b.wt.) petals administered orally to HFD-fed rats for 6 weeks. Physiological parameters like body weight,
food and water intake, fat pad analysis and biochemical parameters like serum lipids, glucose, Serum Glutamate Oxaloacetate
Transaminase (SGOT)  and  Serum  Glutamate  Pyruvate  Transaminase  (SGPT),  serum  urea  and  creatinine  levels  were  measured.
Results: Treatment with powder of R.  damascena  flower petals to HFD-induced obese rats resulted in a significant reduction in body
weight gain, fat pads, serum lipids, glucose, SGOT, SGPT and creatinine levels as compared to rats fed HFD alone. Further, the extract also
showed a significant increase in High-Density Lipoprotein (HDL) levels. Conclusion: These results exhibit that the R. damascena flower
possesses significant anti-obesity potential.
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INTRODUCTION
The WHO defined obesity as a condition of abnormal or
excessive fat accumulation in adipose tissue, to the extent that
health may be impaired1. Its prevalence is on a continuous rise
in all age groups of many of the developed countries in the
world. Statistical data revealed that the problem of obesity
had increased from 12-20% in men and 16-25% in women
over the last ten years.  Recent  studies  suggest  that  nearly
15-20% of the middle-aged European population are obese
and that in the USA alone it is responsible for as many as
3,00,000 premature deaths each year2.In developing countries,
obesity is more common in middle-aged women, people of
higher socioeconomic status and those living in urban
communities. Furthermore, it tends to be associated with
lower socioeconomic status, especially in women and the
urban-rural differences are diminished or even reversed. A
complex, multifactorial disease with genetic, behavioural,
socioeconomic and environmental origins, obesity raises the
risk of debilitating morbidity and mortality3,4. Previous
researches on obesity in India revealed that the prevalence of
obesity to be higher among women5-9 and economically
better off persons10-12. In the Indian Women’s Health Study the
overall prevalence of central obesity among women between
25-64 year of ages was 55%. The BMI, sedentary lifestyle,
family history of excess fat intake were found to be significant
risk factors for central obesity13.
Rosa damascena Mill. is the hybrid between R. gallica and
R. Phoenicia and is a member of the Rosaceae family with
more than 200 species and 18,000 cultivars around the world.
R. damascena as the king of flowers has been the symbol of
love, purity, faith and beauty since  the  ancient  times14.  The
R. damascena Mill. is known as “Gol-e-Mohammadi” in Persian.
This plant is called Damask rose because it was originally
brought to Europe from Damascus15. The R. damascena (RD)
has attracted considerable attention in horticulture,
biochemistry and in pharmacology because of the fragrance
of the flowers and the high content of its biologically active
substances16. The plant is  also  reported  for its various
activities namely, hypolipidemic17-19, antidiabetic20-21,
antioxidant22-24, hepatoprotective25-27, immunomodulatory28,
cardioprotective29,  anti-stress30 and anticonvulsant31-33. The RD
is  being  used  traditionally  in  many  Unani  formulations
since long back.  It  is  one  of  the  ingredients of such an
Unani formulation named as Safoof-e-Muhazzila polyherbal
formulation used in the Unani System of Medicine for the
treatment of obesity for ages. The formulation is a classical
Unani pharmacopeial formulation used in hyperlipidemia34.
This research work was, therefore, designed to explore the
anti-obesity potential of R. damascena on high-fat diet-
induced Wistar albino rats.
MATERIALS AND METHODS
Study area: The study was carried out from February, 2012 to
March, 2013.
Plant material and authentication: The drug was purchased
from a herbal distributer, Shamsi Dawakhana, Ballimaran,
Delhi and authenticated by Dr H.B. Singh, Scientist F and Head,
Raw Materials Herbarium and Museum, National Institute of
Science Communication and Information Resources (NISCAIR),
New Delhi. Voucher specimens of drugs were deposited in the
Raw Materials Herbarium and Museum, NISCAIR, New Delhi,
with reference number Ref. NISCAIR/RHMD/consult/-2010-
11/1705/05. The petals of the drug were dried in shade at
room temperature and powdered showed in Fig. 1.
Animals and diet: Female Wistar albino rats, 6-8 weeks old,
weighing 100-150 g were procured from Central Animal
House Facility, Jamia Hamdard, New Delhi. The study was
approved by Institutional Animal Ethics Committee (ref no.
173/CPCSEA/747/20.07.2011). The animals were kept in
polypropylene cages (6 in each) under standard laboratory
conditions (room temperature at 25±2EC with 12 hrs light
and 12 hrs dark (day and night cycle) and had free access to
commercial pellet diet (Lipton rat feed Ltd., Pune, Maharastra)
and tap water ad  libitum.
Fig. 1: Dried petals Rosa damascena Mill.
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Preparation of doses: The powder of the drug (passed
through sieve no. 120) was suspended in Carboxy Methyl
Cellulose (CMC, 1%) and administered orally by gavage in
volume not greater than 1 mL 100 gG1 b.wt., daily for 6 weeks.
The prepared suspension was stored in amber-coloured
bottles in the refrigerator.
Induction of obesity by feeding HFD: High Fat Diet (HFD) was
purchased from the National Institute of Nutrition (NIN), Jamia
Osmania, Hyderabad, Andhra Pradesh, India. The composition
of HFD is given in Table 1.
Dosing  schedule:   The   duration   of   the   experiment   was
6 weeks. The rats were divided into 4 groups of 6 animals
each. The group I served as normal control receiving a normal
diet only. Group II served as High Fat Diet (HFD) control
receiving only a high-fat diet. Group III served as standard
which received HFD and orlistat (STD) 25 mg kgG1 b.wt.35. The
calculated dose of each rat was 1-1.5 mL adjusted according
to the weight of each rat. The human dose of the formulation
given in National Formulary of Unani Medicine as 5-10 g, the
dose of RD with the mean dose 7.5 g by using the formula
given by Reagan-Shaw et al.36 was calculated. The details of
the treatment schedule, dose and route of administration used
during the experimental work are given in Table 2.
Physiological parameters
Weight measurement: The body weight of each rat was
recorded once a week for six weeks using a standard weight
machine with the net weight gain and calculated35.







Ground nut oil 0.125
Thallow 0.950
Mineral mixture (AIN) 0.175
Vit. Mixture (AIN) 0.055
Table 2: Details of anti-obesity studies
Groups, route of administration-oral n
Normal control (NC) 6
Obese control (HFD) 6
HFD+Orlistat std (25 mg kgG1), (STD) 6
HFD+RD, 214 mg kgG1 6
N: Number of rats, NC: Normal control, HFD: High-fat diet, STD: Orlistat, RD: Rosa
damascena
Food and water intake: Food and water intake were
measured daily for 42 days in each group and the average was
calculated for a week37. 
Organ and fat pad weights: The animals were sacrificed using
light ether anaesthesia and then different organs like kidney,
liver, heart and spleen and fat pads- mesenteric, perirenal and
uterine were removed and weighed38.
Biochemical investigations: On day 42, before sacrificing
animals the blood was collected by sino-orbital puncture and
serum was separated. Levels of glucose, total cholesterol,
High-Density Lipoprotein cholesterol (HDL), triglycerides,
SGOT, SGPT, uric acid  and  creatinine level were measured
from the separated serum using biochemical kits provided by
Span Diagnostics Ltd. (Surat, India). Estimation of Total
Cholesterol (TC), High-Density Lipoprotein (HDL) and Low-
Density Lipoprotein (LDL)39-40 and triglycerides41, Serum
glucose42, serum glutamate oxaloacetate transaminase (SGOT)
and serum glutamate pyruvate transaminase (SGPT)43; Serum
uric acid44 and serum creatinine45 were carried out as the
methods described.
Statistical  analysis:  Data  were  expressed  as mean±SEM of
n = 6. Data were analyzed by one-way analysis of variance
(ANOVA) and then differences among means were analyzed
using the Turkeys multiple comparisons post hoc-test.
Differences were considered significant at p<0.05. 
RESULTS AND DISCUSSION
Body weight variation: Obesity is considered to be a disorder
of energy balance, occurring when energy expenditure is no
longer in equilibrium with daily energy intake, to ensure body
weight homeostasis37,46,47. As shown in Table 3, there was a
significant (p<0.001) increase in body weight of the High Fat
Diet   (HFD)   group   when   compared   to  the  normal  control
Table 3: Effect of treatment on body weight
Total increase in body Reduction of body weight





All values are given as Mean±SEM, n = 6, aCompared with normal control group,
bCompared with HFD group, cCompared with SMM, ns: p>0.05, *p<0.05,
**p<0.01, ***p<0.001, NC:  Normal  control,  HFD:  High  fat  diet,  STD:  Orlistat,
RD: Rosa damascena
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Fig. 2: Effects of treatment on water intake
NC: Normal control, HFD: High fat diet, STD: Orlistat, RD: Rosa damascena
Table 4: Effects of treatment on food intake
Weeks NC HFD STD RD
1 13.33±0.76 21.00±1.155 20.32±0.282 17.94±0.856
2 12.273±0.32 20.265±1.75 18.37±0.112 19.37±1.3
3 12.667±0.66 19.76±0.77 18.54±0.856 18.84±2.654
4 14.833±1.47 18.47±0.79 17.94±0.447 17.39±0.84
5 15.833±1.195 18.49±0.477 16.19±0.6 19.75±0.609
6 17.835±0.945 18.41±0.73 16.84±0.365 18.37±0.5
NC: Normal control, HFD: High fat diet, STD: Orlistat, RD: Rosa damascena
group, the result is following that of Latha et al.35. All the
treatment groups showed a significant (p<0.001) reduction in
body weight compared to the HFD group. The treatment
groups, STD and RD showed significant reduction (p<0.001) in
body weight gain, 53.22±0.75 and 22.43±1.34%, respectively
compared to the HFD group.
Food intake: Consumption of the HFD led to obesity because
it initiates the development of a positive energy balance
leading to an increase in fat deposition. In the current study,
rats of the HFD group consumed significantly more food than
the control rats throughout the experiment. So, their caloric
intake was increased and they showed a large increase in
perirenal visceral adipose tissue mass, suggesting that the
excess energy led to the buildup of adiposity. This is the
source of the increase in body weight48. There was a significant
(p<0.001) increase in food intake(18.41±0.73-21±1.155) in
HFD fed group compared to the normal control(12.273±0.32-
17.835±0.945)while all the treatment groups showed non-
significantly (p>0.05) lower food intake except STD (p<0.01)
compared to HFD. The results of the experiment showed that
HFD fed animals took more food during the experiment while
treatment groups took slightly lower food intake with
fluctuations of lower and higher intake in subsequent weeks
as compared to the HFD group in Table 4.
Water intake: There was no significant change of water intake
observed in HFD fed rats as well as in treatment groups.
Fluctuations in water intake were observed in HFD and
treatment groups throughout the experiment. The results of
the experiment showed that the treatments with standard and
RD have no effect on the behaviour of animals for water intake
in Fig. 2.
Organs weight analysis: The HFD fed animals showed
significant (p<0.001) increase in weight of heart
(0.8286±0.017 g), liver (10.636±0.45 g), spleen
(0.7198±0.024 g)  and  kidney  (1.826±0.051  g) in
comparison to normal control animals. Treatment with RD
resulted in a significant decrease in weight of  heart, liver,
spleen and kidney (0.7847±0.028, 8.171±0.20, 0.6527±0.007
and    1.645±0.096     g,    respectively)   as   compared    to
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Table 5: Organs weight analysis
Groups Heart (g) Liver (g) Spleen (g) Kidneys (g)
NC 0.7393±0.015 7.504±0.113 0.6075±0.014 1.381±0.011
HFD 0.8286±0.017***a 10.636±0.45***a 0.7198±0.024***a 1.826±0.051***a
STD+HFD 0.765±0.045***b 7.74±0.34***b 0.628±0.003***b 1.487±0.042*b
RD+HFD 0.7847±0.028***b 8.171±0.20**b 0.6527±0.007**b 1.645±0.096*b
All values are given as Mean±SEM, n = 6, aCompared with Normal Control group, bCompared with HFD group, ns: p>0.05, *p<0.05, **p<0.01, ***p<0.001, NC: Normal
control, HFD: High fat diet, STD: Orlistat, RD: Rosa damascena
Table 6: Fat pad analysis
Groups Mesenteric Perirenal Uterine
NC 0.634±0.03 0.648±0.04 0.664±0.028
HFD 1.2345±0.11***a 1.145±0.08***a 1.264±0.145***a
STD+HFD 0.724±0.08***b 0.68±0.02***b 0.713±0.031***b
RD+HFD 0.873±0.08**b 0.832±0.035**b 0.946±0.154*b
All values are given as Mean±SEM, n = 6, aCompared with Normal Control group, bCompared with HFD group, ns: p>0.05, *p<0.05, **p<0.01, ***p<0.001, NC: Normal
control, HFD: High fat diet, STD: Orlistat, RD: Rosa damascena
Table 7: Effects of treatment on total cholesterol
Groups TC (mg dLG1) HDL (mg dLG1) LDL (mg dLG1) VLDL (mg dLG1) Atherogenic index Triglycerides (mg dLG1)
NC 64.34±1.16 25.375±0.36 21.514±0.62 17.446±0.488 1.535±0.2 87.23±1.53
HFD 162.48±2.45***a 9.03±0.51***a 109.72±0.81*a 43.73±2.39*a 16.993±2.34*a 218.65±1.69***a
STD+HFD 69.87±1.87***b 24.64±56***b 26.446±0.65*b 18.784±0.36*b 1.835±0.12*b 93.92±1.24ns
RD+HFD 116.37±2.01***b 14.33±0.17**b 69.448±5.47*b 32.592±1.76*b 7.121±1.34*b 162.96±1.71***a
All values are given as Mean±SEM, n = 6, aCompared with normal control group, bCompared with HFD group, cCompared with SMM, ns: p>0.05, *p<0.05, **p<0.01,
***p<0.001, NC: Normal control, HFD: High fat diet, STD: Orlistat, RD: Rosa damascena. TC: Total cholesterol, LDL: Low-density lipoproteins, HDL: High-density lipoprotein,
VLDL: Very-low-density lipoproteins
Table 8: Effects of treatment on serum glucose level
Reduction of





All values are given as Mean±SEM, n = 6,  aCompared with normal control group,
bCompared with HFD group, cCompared with SMM, ns: p>0.05, *p<0.05,
**p<0.01, ***p<0.001,  NC:  Normal  control,  HFD:  High  fat  diet,  STD:  Orlistat,
RD: Rosa damascena
Fat pad analysis: As shown in Table 6, administration of HFD
produced a highly significant (p<0.001) increase in weight of
mesenteric, perirenal and uterine fat pads (1.2345±0.11,
1.145±0.08 and 1.264±0.145 g, respectively) when compared
to normal control. Treatment with standard and RD exhibited
a decrease in mesenteric, perirenal and uterine fat pads
(0.873±0.08, 0.832±0.035 and 0.946±0.154 g, respectively)
compared to HFD fed group.
Biochemical parameters
Total cholesterol: Increased fat consumption has been
associated with the risk of hyperlipidaemia via alteration of
Total Cholesterol (TC) and Triglycerides (TG) levels in plasma
and tissues49. On the other hand, elevated levels of plasma
Low-Density Lipoproteins (LDL-C) and TG, accompanied by
reduced High-Density Lipoproteins (HDL-C) levels are
associated   with   an  increased  risk  of  Cardiovascular
Diseases (CVDs). Consumption of a high-fat diet accelerates
the development of obesity and heart problems35,50.
Consumption of HFD led to a significant increase
(p<0.001) in total cholesterol (TC, 162.48±2.45 mg dLG1),
triglycerides (TGs, 218.65±1.69 mg dLG1), low-density
lipoproteins  (LDL,  109.72±0.81  mg   dLG1),   VLDL
(43.73±2.39 mg dLG1) and decrease in high-density
lipoprotein (HDL, 9.03±0.51 mg dLG1) cholesterol compared
to normal diet group. Treatment with standard and RD
showed a significant decrease in TC (116.37±2.01 mg dLG1),
TGs (162.96±1.71 mg dLG1), LDL (69.448±5.47 mg dLG1), VLDL
(32.592±1.76 mg dLG1) and an increase in HDL cholesterol
level compared to animals of HFD fed group given in Table 7.
These results suggested that RD has anti-hyperlipidemic
effects and are in agreement with previous reports17-34.
Blood glucose: Intake of high-fat diet significantly increased
(p<0.001) the level of serum glucose in the HFD group
(192.79±1.05 mg dLG1) compared to the normal control
group(88.74±1.49  mg dLG1). Current findings showed that
the treatment with RD significantly decreased (p<0.001) the
level of serum glucose compared to the HFD group. As shown
in Table 8 treatment with standard and RD significantly
(p<0.001) reduced the level of glucose (154.30±2.61 mg dLG1).
The  percentage  reduction  was,  49.95±0.55%    for   standard
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Table 9: Effects of treatment on SGPT and SGOT
Reduction of SGPT Reduction of SGOT
Groups SGPT (IU LG1) compared to HFD (%) SGOT (IU LG1) compared to HFD (%)
NC 55.35±1.55 91.47±2.27 
HFD 129.97±6.49***a 100 189.5±2.28***a 100 
STD+HFD 60.33±1.73***b 53.58±2.49***b 103.8±1.79***b 45.20±1.62***b
RD+HFD 95.48±2.86***b 26.53±3.65***b 148.6±3.21***b 21.54±1.99***b
All values are given as Mean±SEM, n = 6, aCompared with normal control group, bCompared with HFD group, ns: p>0.05, *p<0.05, **p<0.01, ***p<0.001, NC: Normal
control, HFD: High fat diet, STD: Orlistat, RD: Rosa damascena
Table 10: Effect of treatment on serum uric acid
Uric acid Reduction of uric acid





All values are given as Mean±SEM, n = 6, aCompared with normal control group,
bCompared with HFD group, NC: Normal control, HFD: High-fat diet, STD: Orlistat,
RD: Rosa damascena
Table 11: Effect of treatment on serum creatinine level
Creatinine Reduction of creatinine





All values are given as Mean±SEM, n = 6, aCompared with normal control group,
bCompared with HFD group, *p<0.001, NC: Normal control, HFD: High-fat diet,
STD: Orlistat, RD: Rosa damascena
(Orlistat) and 19.96±1.05% for RD (p<0.001) respectively
compared to the HFD group. The above findings showed that
RD has the potential to reduce the elevated level of serum
glucose due to obesity and its related disorders. These results
are in line with the previous reports20-21.
SGPT and SGOT: Obesity is the major risk factor for complex
and chronic liver disorders51. These liver disorders begin as
steatosis and cause steatohepatitis, cirrhosis, liver failure and
hepatocellular carcinoma52-54. In obesity, the liver is
bombarded by the Free Fatty Acids (FFA) that pour out of the
adipose tissue into the portal blood. This can directly cause
inflammation within the liver cells, which then release further
pro-inflammatory cytokines, leading to more hepatocytes
injury and affecting the integrity of liver cells55. As shown in
Table 9, there was a significant increase (p<0.001) in the
activity  of  SGPT  (129.97±6.49  IU  LG1)  and SGOT
(189.5±2.28 IU LG1) in HDF fed group compared to the normal
control group (55.35±1.55, 91.47±2.27 IU LG1, respectively).
Administration of standard and RD produced significant
lowering effects on the activity of SGPT (95.48±2.86 IU LG1)
and SGOT (148.6±3.21 IU  LG1)  compared  to  HFD fed
animals.
Treatment with standard and RD doses significantly
(p<0.001) reduced the level of SGPT and SGOT. The percent
reduction was 53.58±2.49 and 26.53±3.65% for SGPT and
45.20±1.62 and 21.54±1.99% for SGOT, respectively, as
compared with HFD fed animals. Treatment with RD and OV
also significantly (p<0.001) reduced the level of SGPT and
SGOT. The above findings showed that the RD has protective
effects on liver injuries caused by obesity and obesity-related
disorders. The results of the experiment are complying with
the previous reports26-27.
Determination of serum uric acid: As shown in Table 10, the
HFD fed rats showed a highly significant (p<0.001) increase in
the concentration of serum uric acid (3.6765±0.11 µg mLG1),
compared to the normal control group (2.42±0.067 µg mLG1)
which agrees with the results of Cindik et al.56. A high-fat diet
induces alteration of renal lipid metabolism by an imbalance
between lipogenesis and lipolysis in the kidney, as well as
systemic  metabolic  abnormalities  and  subsequent renal
lipid accumulation leading to renal injury55,57. Treatment with
standard orlistat (STD) significantly (p<0.001) reduced
(26.41±4.15%)  while  treatment  with  RD  (10.54±4.01%)
non-significantly (p>0.05) reduced the level of serum uric acid
compared to the HFD group. 
Serum creatinine: As shown in Table 11, the HFD fed rats
showed a highly significant (1.3945±0.053 mg dLG1) increase
in the concentration of serum creatinine, compared to the
normal control group (0.692±0.04 mg dLG1) which is in
agreement   with   the   results  of  Amin  and  Nagy55  and
Cindik et al.56. Treatment with standard orlistat (STD) and RD
significantly reduced the level of serum creatinine
(0.9945±0.057 and 1.219±0.055 mg dLG1, respectively)
compared to HFD (1.3945±0.053 mg dLG1) fed animals.
CONCLUSION
In the present study, treatment with R. damascena
significantly reduces the increased body weight, weight of
heart, liver, spleen and kidney and fat pats, decreases
cholesterol,    triglycerides,   glucose,   SGOT,   SGPT   level   and
19
Res. J. Phytochem., 15 (1): 14-22, 2020
creatinine level while increases HDL level. In conclusion, the
results obtained from the present study signify the anti-
obesity effect of R. damascena, which is comparable to that of
orlistat. However, the exact mechanism(s) of this effect should
be clarified in further studies. 
SIGNIFICANCE STATEMENT 
This study discovered the ameliorating effects of Rosa
damascena in obesity and related disorders. This study will
help the researchers to uncover the critical areas of diabetic
disorders, hepatotoxicity and hypercholesterolemia that many
researchers were not able to explore. Thus a new theory on
overweight and obesity may be arrived at.
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